Dihydroartemisinin–Piperaquine-Augmented Malaria Chemoprevention in Pregnant Women with HIV

Adding this monthly preventive treatment to daily co-trimoxazole prevented two of three malaria infections in pregnant women with HIV and on dolutegravir-based treatment.

Daily co-trimoxazole is WHO-recommended standard care for pregnant women with HIV in malaria-endemic areas, but resistance of Plasmodium falciparum to antifolates threatens their effectiveness. Investigators in Kenya and Malawi assessed whether adding monthly dihydroartemisinin–piperaquine is more effective than daily co-trimoxazole alone. Pregnant women with HIV on dolutegravir-based combination antiretroviral therapy (cART) were randomized to daily co-trimoxazole plus monthly dihydroartemisinin–piperaquine (daily for 3 days) or daily co-trimoxazole plus monthly placebo. The primary endpoint was maternal or placental malaria from 2 weeks after the first study dose to delivery.

Among almost 900 pregnant women between 16 and 28 weeks' gestati…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Dihydroartemisinin–Piperaquine-Augmented Malaria Chemoprevention in Pregnant Women with HIV

Topics

Reviewing Author